Last reviewed · How we verify
Placebo for ferinject
A placebo control contains no active pharmaceutical ingredient and produces no pharmacological effect.
A placebo control contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in clinical trials for iron deficiency anemia (comparator to Ferinject).
At a glance
| Generic name | Placebo for ferinject |
|---|---|
| Also known as | NaCl |
| Sponsor | Maastricht University Medical Center |
| Modality | Small molecule |
| Therapeutic area | Clinical Trial Control |
| Phase | FDA-approved |
Mechanism of action
Placebos are inert substances used as controls in clinical trials to establish the efficacy of an active drug by comparison. They rely on the placebo effect—psychological and physiological responses to the expectation of treatment—rather than any direct molecular mechanism. In this case, it serves as a comparator for Ferinject (ferric carboxymaltose), an iron replacement therapy.
Approved indications
- Control arm in clinical trials for iron deficiency anemia (comparator to Ferinject)
Common side effects
Key clinical trials
- Intravenous Iron for Treatment of Anaemia Before Cardiac Surgery (PHASE4)
- IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study (PHASE2, PHASE3)
- Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia (PHASE3)
- Intravenous Iron Effects on Performance at High Altitude (PHASE4)
- Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality (PHASE4)
- Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study (PHASE3)
- The Role of Intravenous Ferritin in Optimizing Postoperative Recovery Following Pancreaticoduodenectomy (NA)
- IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for ferinject CI brief — competitive landscape report
- Placebo for ferinject updates RSS · CI watch RSS
- Maastricht University Medical Center portfolio CI